A phase Ib/II trial of Imprime PGG in combination with atezolizumab and bevacizumab in patients with metastatic colorectal cancer

Trial Profile

A phase Ib/II trial of Imprime PGG in combination with atezolizumab and bevacizumab in patients with metastatic colorectal cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; PGG-glucan (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 29 Nov 2017 New trial record
    • 28 Nov 2017 According to a Biothera Pharmaceuticals, Inc. media release, this trial will enroll approximately 40 patients in the initial phase.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top